Edition:
United States

Biotechnology & Medical Research

Page 1

Neuron Bio to launch offer to delist Neol Biosolutions

Monday, 14 Nov 2016 02:26am EST

Neuron Bio SA : To launch an offer to buy 100 percent of Neol Biosolutions . Says listing of Neol did not fulfill objectives that Neuron expected . Values Neol at over 30 million euros ($32.41 million), three times above its current market capitalization . To launch an offer for 30.221 percent of Neol's shares that is doesn't own, to offer 5 shares of Neuron Bio per each 4 shares of Neol .Plans to restructure its business, Neol will become a private company again.

Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe

Monday, 29 Aug 2016 05:19pm EDT

Albany Molecular Research Inc : Announced a restructuring plan with respect to certain operations in United States and Europe . Restructuring plan in connection with previously announced acquisition of prime European therapeuticals S.P.A Euticals . Under plan, co expects to incur certain charges related to reduction in force, other transition activities between $5.7 - $7.3 million . Cash charges will consist of $5.5 - $7.1 million of employee and other related costs and will primarily be paid during second half of 2016 .Company expects majority of these charges to be recorded in second half of 2016..

Flamel technologies announces shareholder approval of cross-border merger

Friday, 12 Aug 2016 07:30am EDT

Flamel Technologies Sa : Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc . Flamel technologies announces shareholder approval of cross-border merger . Received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger .Under terms of reincorporation, Flamel will merge with and into its wholly owned subsidiary, Avadel Pharmaceuticals Ltd.

EPS Holdings says merger between units

Tuesday, 26 Jul 2016 03:16am EDT

EPS Holdings Inc <4282.T> : Says co's wholly owned sub-subsidiary EP-S0G0 Co., Ltd to merge with co's wholly owned subsidiary Sogo Rinsho Holdings Co Ltd, effective on Oct. 1 .Says Sogo Rinsho Holdings Co Ltd to be dissolved after the transaction.

Replicel Life Sciences continues restructuring with share structure consolidation

Friday, 22 Jul 2016 09:20pm EDT

Replicel Life Sciences Inc : Replicel Life Sciences continues restructuring with share structure consolidation .Says its board of directors has authorized a plan to proceed with a consolidation of its outstanding common shares.

Replicel Life Sciences continues restructuring with share structure consolidation

Friday, 22 Jul 2016 07:05pm EDT

Replicel Life Sciences Inc : Replicel Life Sciences continues restructuring with share structure consolidation .Says its board of directors has authorized a plan to proceed with a consolidation of its outstanding common shares.

Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln

Tuesday, 14 Jun 2016 06:39am EDT

Infinity Pharmaceuticals Inc : Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016 . Expects to incur total restructuring costs ranging from approximately $6 to $8 million . Expects to record a majority of restructuring charges as research and development expenses during three months ended june 30, 2016 . Currently expects $5 million in future cash outlays related to severance, benefits and related costs .Continuing to review potential impact of restructuring, unable to estimate any additional restructuring costs or charges at this time.

Mologen completes portfolio review

Thursday, 9 Jun 2016 05:28am EDT

Mologen AG : Mologen completes portfolio review: shift from research to product- and market-oriented company . Implementation of new structure is expected to be completed by end of 2016 . Decided to implement a strategy program to concentrate its business activities on further development and commercialisation of its main product, i.e. Lefitolimod including successor molecule EnanDIM .Plans to outsource its production activities to a specialist contract manufacturer which is still to be chosen.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary